← Back to Clinical Trials
Recruiting NCT04904757

NCT04904757 Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04904757
Status Recruiting
Phase
Sponsor University of Virginia
Condition Mammographic Breast Density
Study Type INTERVENTIONAL
Enrollment 210 participants
Start Date 2019-09-19
Primary Completion 2022-12

Eligibility & Interventions

Sex Female only
Min Age 40 Years
Max Age 69 Years
Study Type INTERVENTIONAL
Interventions
Contrast-enhanced spectral mammography (CESM)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 210 participants in total. It began in 2019-09-19 with a primary completion date of 2022-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to evaluate how well women may adopt a Contrast-enhanced Spectral Mammography (CESM) as their yearly breast screening test compared to the standard 2-D or 3-D mammogram.

Eligibility Criteria

Inclusion Criteria: * • Female * 40 to 69 years * Previous normal mammogram (BI-RADS 1 or 2) showing heterogeneous or extremely dense breast tissue within last 24 months * Scheduled for screening mammogram as part of the patient's clinical care Exclusion Criteria: * • No mammogram within last 24 months * Fatty or scattered fibroglandular tissue on last mammogram * History of allergy to iodinated contrast * History of renal disease or renal function abnormalities * Pregnant women * History of diabetes * History of paraproteinemia syndromes such as multiple myeloma * History of collagen vascular disease * History of vascular disease (coronary artery disease, myocardial infarction, carotid disease, peripheral vascular disease, or known visceral artery disease) * Previously identified as high risk for breast cancer (\>20% lifetime risk) * Asthma * Sickle Cell Anemia * Currently on Dialysis

Contact & Investigator

Central Contact

Kathy L Repich, RN

✉ klr3b@virginia.edu

📞 4342434540

Frequently Asked Questions

Who can join the NCT04904757 clinical trial?

This trial is open to female participants only, aged 40 Years or older, up to 69 Years, studying Mammographic Breast Density. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04904757 currently recruiting?

Yes, NCT04904757 is actively recruiting participants. Contact the research team at klr3b@virginia.edu for enrollment information.

Where is the NCT04904757 trial being conducted?

This trial is being conducted at Charlottesville, United States.

Who is sponsoring the NCT04904757 clinical trial?

NCT04904757 is sponsored by University of Virginia. The trial plans to enroll 210 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology